Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation

Table 1 Demographic and clinical characteristics of 494 patients by glucose tolerance subgroups

	All patients	NGT	IGT	PTDM	P-value
Number of patients	494	377	66	51
Age (years)	52.5 ± 14.0	50.5 ± 14.2	58.1 ± 10.8	60.6 ± 11.4	< 0.001
Donor (% living)	152 (30.8)	121 (32.1)	22 (33.3)	9 (17.6)	0.10
Gender (% males)	343 (69.2)	251 (66.6)	51 (77.3)	39 (76.5)	0.11
BMI (kg/m²)	25.9 ± 4.5	25.5 ± 4.4	26.4 ± 4.5	27.4 ± 5.1	0.01
Hemoglobin (g/dL)	13.7 ± 1.7	13.7 ± 1.7	13.7 ± 1.7	13.8 ± 1.6	0.83
HbA1c (%)	5.6 ± 0.5	5.5 ± 0.4	5.9 ± 0.4	6.4 ± 0.7	< 0.001
Fasting plasma glucose
(mmol/L)	5.6 ± 0.9	5.4 ± 0.5	5.8 ± 0.5	7.4 ± 1.0	< 0.001
[mg/dL]	[100.9 ± 16.2]	[97.3 ± 9.0]	[104.5 ± 9.0]	[133.3 ± 18.0]
2 h plasma glucose after OGTT
(mmol/L)	6.7 ± 2.5	5.6 ± 1.1	8.9 ± 0.9	11.3 ± 3.6	< 0.001
[mg/dL]	[117.1 ± 45.0]	[100.9 ± 19.8]	[160.4 ± 16.2]	[203.6 ± 64.9]
Creatinine (μmol/L)	117 ± 40	115 ± 38	125 ± 46	118 ± 45	0.20
Total cholesterol
(mmol/L)	4.9 ± 1.0	4.8 ± 1.0	5.1 ± 1.1	5.0 ± 1.0	0.10
[mg/dL]	[88.3 ± 18.0]	[86.5 ± 18.0]	[91.9 ± 19.8]	[90.1 ± 18.0]
LDL-cholesterol
(mmol/L)	2.9 ± 0.9	2.8 ± 0.8	3.0 ± 0.9	2.9 ± 0.9	0.17
[mg/dL]	[52.3 ± 16.2]	[50.5 ± 14.4]	[54.1 ± 16.2]	[52.3 ± 16.2]
Triglycerides
(mmol/L)	1.6 ± 0.8	1.5 ± 0.8	1.8 ± 1.0	2.0 ± 1.0	< 0.001
[mg/dL]	[28.8 ± 14.4]	[27.0 ± 14.4]	[32.4 ± 18.0]	[36.0 ± 18.0]

Difference between subgroups given in mean ± standard deviation or number (%), evaluated by the ANOVA test for continuous variables and Pearson chi-square test for categorical variables. P-values are reported to 2 decimals. Abbreviations: BMI, body mass index in kg/m2; IGT impaired glucose tolerance, LDL low density lipoprotein, NGT normal glucose tolerance, OGTT oral glucose tolerance test, PTDM post-transplantation diabetes mellitus

ISSN: 1471-2369